This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - teriflunomide for treating relapsing-remitting multiple sclerosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Teriflunomide is an immunomodulatory disease-modifying therapy

  • has a UK marketing authorisation for 'the treatment of adult patients with relapsing remitting multiple sclerosis'
  • is anti-inflammatory and works by blocking proliferation of stimulated lymphocytes
  • exact mechanism of action for teriflunomide is not fully understood
    • thought to reduce the number of activated lymphocytes, which would cause inflammation, and damage myelin in the central nervous system

Adverse effects include:

  • diarrhoea, alopecia, nausea and increased levels of alanine aminotransferase

NICE have stated that teriflunomide is recommended for treating adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years)

  • only if they do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis

For full details see the summary of product characteristics.

Reference:

  1. NICE (January 2014). Teriflunomide for treating relapsing-remitting multiple sclerosis

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.